Search clinical trials for: Serum Iron overload due to transfusions

Total 475416 results

Novartis Pharmaceuticals

Completed

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Transfusional Hemosiderosis

United States
ApoPharma

Completed

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload (TWICE)

Iron Overload Due to Repeated Red Blood Cell Transfusions

United States, Canada, Greece, Italy
Shire

Terminated

Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)

Iron Overload Due to Repeated Red Blood Cell Transfusions

Canada, United States, Thailand, Italy, United Kingdom
Shire

Terminated

Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

Iron Overload Due to Repeated Red Blood Cell Transfusions

United States, Canada, Lebanon, Italy, Egypt
Sheba Medical Center
Hadassah Medical Organization; Kaplan Medical Center; Tel Aviv Medical Center; Ziv...

Completed

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Myelodysplastic Syndrome With Low-grade Lesions | Iron Overload Due to Repeated Red Blood Cell Transfusions

Israel
Novartis Pharmaceuticals

Completed

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Anemia, Sickle Cell

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

Myelodysplastic Syndromes | Transfusion Dependent Iron Overload

Germany
Children's Hospital Los Angeles
Novartis Pharmaceuticals

Terminated

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

Anemia, Sickle Cell | Transfusion Hemosiderosis

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

Iron Overload

Germany
Novartis Pharmaceuticals

Completed

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Beta-Thalassemia

United States
Ain Shams University

Unknown

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Sickle Cell Disease | Beta-thalassemia Major | Iron Hemosiderosis

Egypt
Novartis Pharmaceuticals

Completed

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) (ESCALATOR)

Iron Overload | Hemosiderosis | Beta-thalassemia Major | Rare Anemia

Egypt, Oman, Saudi Arabia, Syrian Arab Republic, Lebanon
Novartis Pharmaceuticals

Completed

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Myelofibrosis | Sickle Cell Disease | Thalassemia | Diamond Blackfan Anemia

United States, Netherlands, Taiwan, Thailand, Italy, Germany, Spain, Canada, Belgium, Greece, Turkey, United Kingdom
Novartis Pharmaceuticals

Completed

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Transfusional Iron Overload in β-thalassemia

United States, Greece, Argentina, Germany, Belgium, Italy, United Kingdom, France, Tunisia, Canada, Turkey, Brazil
Novartis Pharmaceuticals

Completed

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Iron Overload | Sickle Cell Disease | Hemolytic Anemia

United States, Canada
Novartis Pharmaceuticals

Completed

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

Anemia | Hemosiderosis

United States, Germany, Belgium, United Kingdom, Italy, Canada, France
Regeneron Pharmaceuticals

Not yet recruiting

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body (FERVENT-1)

Non-transfusion Dependent Beta-thalassemia (NTDT)
Haukeland University Hospital
Novartis

Withdrawn

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (DefeHEMY)

Myelodysplastic Syndromes | Hemochromatosis

Norway
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Transfusion-dependent Anemia

Egypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
Boston Children's Hospital
Novartis

Completed

Pilot Study for Patients With Poor Response to Deferasirox

Sickle Cell Disease | Thalassemia Major | Transfusion-dependent Hemachromatosis

United States
University of Utah

Terminated

The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin Levels

Iron Overload

United States
Cairo University

Completed

Effect of Intramuscular Progesterone Supplementation on Clinical and Ongoing Pregnancy Rates in Patients With Low Serum Progesterone Levels on the Day of Embryo Transfer in Artificial Frozen Cycles

Frozen Embryo Transfer | Progesterone Supplementation | Serum Progesterone Levels | Clinical Pregnancy Rates | Ongoing Pregnancy Rates

Egypt
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Transfusional Hemosiderosis | Chronic Anemia

Japan, Turkey, Spain, Poland, Singapore
Shire

Terminated

Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

Beta-Thalassemia | Transfusional Iron Overload

United States, Lebanon, Canada, Italy, Turkey
Shire

Completed

Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

Beta-thalassemia | Transfusional Iron Overload

United States, United Kingdom, Italy, Thailand, Turkey
Shire

Withdrawn

Treatment of Iron Overload Requiring Chelation Therapy

Metabolic Diseases | Iron Metabolism Disorders | Iron Overload | Beta-thalassemia | Transfusional Hemosiderosis | Transfusional Iron Overload | Iron Chelation
Novartis Pharmaceuticals

Completed

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Transfusional Iron Overload | β-thalassemia

Italy
University of Campania "Luigi Vanvitelli"

Completed

Endocrine Function During Deferasirox Therapy

Iron Overload | Endocrine; Complications | Transfusion-dependent Thalassemia

Italy
Baylor College of Medicine

Terminated

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO (THALLO)

Thalassemia

United States
Novartis Pharmaceuticals

Completed

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

Transfusion-dependent Iron Overload

Egypt, Greece, Hong Kong, Taiwan, Germany, United Kingdom, Belgium, Italy, Spain, France, Israel, Korea, Republic of, Turkey, China, Australia, Denmark, Austria, Switzerland, Netherlands, South Africa, Lebanon, Malaysia, Thailand
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Cardiac Iron Overload | Transfusion-dependent β-thalassemia Patients

Greece
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients

Aplastic Anemia

Russian Federation
Rennes University Hospital

Completed

Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.

Diagnosis | Hemochromatosis, Type 4 | Ferroportin Disease | Dysmetabolic Hepatosiderosis

France
Children's Hospital of Philadelphia
Ann & Robert H Lurie Children's Hospital of Chicago; The Cooley's Anemia Foundation...

Completed

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Thalassemia Major With Severe Transfusional Iron Overload

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditions

United States
Masonic Cancer Center, University of Minnesota

Completed

Iron Overload in Patients Undergoing Donor Stem Cell Transplant

Cancer | Hematopoietic Stem Cell Transplantation | Allogeneic Hematopoietic Cell Transplantation

United States
Novartis Pharmaceuticals

Completed

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Chronic Iron Overload Due to Transfusion-dependant Anemias

Italy, Austria, Thailand, Spain, Germany, Mexico, Malaysia, Greece, United Kingdom, France, Saudi Arabia, United Arab Emirates, Lebanon, Russian Federation, United States, Argentina
Novartis Pharmaceuticals

Completed

An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)

Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia

Australia
Novartis Pharmaceuticals

Completed

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Transfusional Iron Overload | β-thalassemia Major | Pediatric Rare Anemia

Italy, France
Novartis Pharmaceuticals

Terminated

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study (MACS1574)

Myelodysplastic Syndrome | Transfusional Iron Overload

Spain, France, Italy, South Africa
Novartis

Completed

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Beta-Thalassemia | Hemosiderosis

Egypt, Lebanon, Oman, Saudi Arabia, Syrian Arab Republic
Novartis Pharmaceuticals

Completed

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Transfusional Iron Overload

United States, Greece, Italy
Novartis

Completed

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Myelodysplastic Syndromes | Hemoglobinopathies | Diamond-Blackfan Anemia | Transfusional Iron Overload | Other Inherited or Acquired Anaemia | MPD Syndrome | Other Rare Anaemias

Australia
Novartis Pharmaceuticals

Completed

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Myelodysplastic Syndrome | Thalassemia

Russian Federation
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Safety, Tolerability, and Efficacy of Deferasirox in MDS

Myelodysplastic Syndromes | Hemosiderosis

Italy
Murdoch Childrens Research Institute
Melbourne Health; Austin Health; Royal Brisbane and Women's Hospital; The University... and other collaborators

Completed

Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary? (Mi-iron)

Hereditary Haemochromatosis

Australia
Columbia University

Completed

High-Tc Susceptometer to Monitor Transfusional Iron Overload

Myelodysplastic Syndromes | Sickle Cell Disease | Aplastic Anemia | Transfusional Iron Overload | Thalassemia Major

United States
Novartis Pharmaceuticals

Completed

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Transfusional Hemosiderosis

Egypt, Spain, United Kingdom, Jordan
Novartis Pharmaceuticals

Completed

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Anemia

United States
Novartis Pharmaceuticals

Completed

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Transfusional Iron Overload

Italy

Search clinical trials for: Serum Iron overload due to transfusions

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations